{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:40Z","timestamp":1789545640483,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05865-y","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T05:01:25Z","timestamp":1720069285000},"page":"2931-2943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021"],"prefix":"10.1007","volume":"103","author":[{"given":"Kai","family":"Kysenius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Anttalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iiro","family":"Toppila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatu","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Lassenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Lievonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raija","family":"Silvennoinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervi","family":"Putkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"5865_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A et al (2020) Multiple myeloma incidence and Mortality around the Globe; interrelations between Health Access and Quality, Economic resources, and patient empowerment. Oncologist 25:e1406\u2013e1413. https:\/\/doi.org\/10.1634\/theoncologist.2020-0141","journal-title":"Oncologist"},{"key":"5865_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A et al (2018) Global burden of multiple myeloma: a systematic analysis for the global burden of Disease Study 2016. JAMA Oncol 4:1221. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"5865_CR3","doi-asserted-by":"publisher","unstructured":"Toppila I, Miettinen T, Lassenius MI et al (2021) Characteristics and survival trends in Finnish multiple myeloma patients\u2014a nationwide real-world evidence study. https:\/\/doi.org\/10.1007\/s00277-021-04481-4. Ann Hematol","DOI":"10.1007\/s00277-021-04481-4"},{"key":"5865_CR4","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-022-04959-9","volume":"101","author":"I Toppila","year":"2022","unstructured":"Toppila I, Kysenius K, Miettinen T et al (2022) Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005\u20132016. Ann Hematol 101:2485\u20132495. https:\/\/doi.org\/10.1007\/s00277-022-04959-9","journal-title":"Ann Hematol"},{"key":"5865_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/ph16030415","volume":"16","author":"WO Elbezanti","year":"2023","unstructured":"Elbezanti WO, Challagundla KB, Jonnalagadda SC et al (2023) Past, Present, and a glance into the future of multiple myeloma treatment. Pharmaceuticals 16:415. https:\/\/doi.org\/10.3390\/ph16030415","journal-title":"Pharmaceuticals"},{"key":"5865_CR6","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1111\/cas.15163","volume":"112","author":"Y Shimazu","year":"2021","unstructured":"Shimazu Y, Mizuno S, Fuchida S-I et al (2021) Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Sci 112:5034\u20135045. https:\/\/doi.org\/10.1111\/cas.15163","journal-title":"Cancer Sci"},{"key":"5865_CR7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/cancers14092277","volume":"14","author":"J Nunnelee","year":"2022","unstructured":"Nunnelee J, Cottini F, Zhao Q et al (2022) Improvement in post-autologous stem cell transplant survival of multiple myeloma patients: a long-term institutional experience. Cancers (Basel) 14:2277. https:\/\/doi.org\/10.3390\/cancers14092277","journal-title":"Cancers (Basel)"},{"key":"5865_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2020.1827253","volume":"62","author":"M Braunlin","year":"2021","unstructured":"Braunlin M, Belani R, Buchanan J et al (2021) Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011\u20132019 oncology clinic electronic health record data. Leuk Lymphoma 62:377\u2013386. https:\/\/doi.org\/10.1080\/10428194.2020.1827253","journal-title":"Leuk Lymphoma"},{"key":"5865_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/2040620718761776","volume":"9","author":"S Mahajan","year":"2018","unstructured":"Mahajan S, Tandon N, Kumar S (2018) The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol 9:123\u2013133. https:\/\/doi.org\/10.1177\/2040620718761776","journal-title":"Ther Adv Hematol"},{"key":"5865_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"5865_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"5865_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M et al (2024) Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 390:301\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"key":"5865_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, R\u00f6gnvaldsson S, Thorsteinsdottir S et al (2021) Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol 106:774\u2013782. https:\/\/doi.org\/10.1111\/ejh.13597","journal-title":"Eur J Haematol"},{"key":"5865_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","volume":"20","author":"JL Dempsey","year":"2019","unstructured":"Dempsey JL, Johns A, Rosko AE, Lazarus HM (2019) The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 20:887\u2013902. https:\/\/doi.org\/10.1080\/14656566.2019.1577822","journal-title":"Expert Opin Pharmacother"},{"key":"5865_CR15","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/cam4.1128","volume":"6","author":"H Gregersen","year":"2017","unstructured":"Gregersen H, Vangsted AJ, Abildgaard N et al (2017) The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med 6:1807\u20131816. https:\/\/doi.org\/10.1002\/cam4.1128","journal-title":"Cancer Med"},{"key":"5865_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W et al (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416\u2013429. https:\/\/doi.org\/10.1111\/ejh.12790","journal-title":"Eur J Haematol"},{"key":"5865_CR17","doi-asserted-by":"publisher","unstructured":"Coluzzi F, Rolke R, Mercadante S (2019) Pain Management in patients with multiple myeloma: an update. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11122037","DOI":"10.3390\/cancers11122037"},{"key":"5865_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"5865_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","volume":"20","author":"C Lin","year":"2020","unstructured":"Lin C, Shen H, Zhou S et al (2020) Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis 20:699. https:\/\/doi.org\/10.1186\/s12879-020-05412-w","journal-title":"BMC Infect Dis"},{"key":"5865_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and Novel agents. CLIN INFECT DIS 49:1211\u20131225. https:\/\/doi.org\/10.1086\/605664","journal-title":"CLIN INFECT DIS"},{"key":"5865_CR21","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873. https:\/\/doi.org\/10.1056\/NEJMra041875","journal-title":"N Engl J Med"},{"key":"5865_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R et al (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J 11:40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4","journal-title":"Blood Cancer J"},{"key":"5865_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43:676\u2013681. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.004","journal-title":"Semin Oncol"},{"key":"5865_CR24","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582\u20132590. https:\/\/doi.org\/10.1056\/NEJMoa070389","journal-title":"N Engl J Med"},{"key":"5865_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2019004309","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J, Munshi NC, Avet-Loiseau H (2021) Risk factors in multiple myeloma: is it time for a revision? Blood 137:16\u201319. https:\/\/doi.org\/10.1182\/blood.2019004309","journal-title":"Blood"},{"key":"5865_CR26","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O et al (2018) Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 103:e412\u2013e415. https:\/\/doi.org\/10.3324\/haematol.2017.183475","journal-title":"Haematologica"},{"key":"5865_CR27","doi-asserted-by":"publisher","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos M-V (2019) Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 9. https:\/\/doi.org\/10.1038\/s41408-019-0183-y","DOI":"10.1038\/s41408-019-0183-y"},{"key":"5865_CR28","first-page":"204","volume":"8","author":"A Roy","year":"2015","unstructured":"Roy A, Kish JK, Bloudek L et al (2015) Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a Model Framework. Am Health Drug Benefits 8:204\u2013215","journal-title":"Am Health Drug Benefits"},{"key":"5865_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4065\/mcp.2009.0426","volume":"85","author":"I Turesson","year":"2010","unstructured":"Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 85:225\u2013230. https:\/\/doi.org\/10.4065\/mcp.2009.0426","journal-title":"Mayo Clin Proc"}],"updated-by":[{"DOI":"10.1007\/s00277-024-05995-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05865-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05865-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05865-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T02:02:00Z","timestamp":1726279320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05865-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5865"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05865-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-024-05995-3","URL":"https:\/\/doi.org\/10.1007\/s00277-024-05995-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Findata, permission THL\/3276\/14.02.00\/2021 and Statistics Finland, permission TK\/1449\/07.03.00\/2022 in accordance with the act on the secondary use of health and welfare data in Finland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"KK, IT, AA and MIL are employees of Medaffcon Oy. TM was an employee of Takeda Finland and Medaffcon Oy. JL has received consultation fees from Amgen, Celgene, Bristol-Myers Squibb, Sanofi, Takeda, Janssen, and travel grants from Janssen, Celgene, Amgen, Novartis, TEVA, Takeda, Roche, Abbvie and Pfizer.AP reports honoraria from Behring and Abbvie and has participated in Scientific Advisory Board meetings organized by Abbvie, Janssen-Cilag, Novartis, Pfizer and Takeda. RS has received research funding from Amgen, BMS, Celgene, Janssen-Cilag and Takeda and honoraria from the same companies (Advisory Board and presentations).MP has received honoraria from Amgen, Celgene, Janssen-Cilag and Takeda (Advisory Board and presentations). TM was an employee of Takeda Finland and Medaffcon Oy. JL has received consultation fees from Amgen, Celgene, Bristol-Myers Squibb, Sanofi, Takeda, Janssen, and travel grants from Janssen, Celgene, Amgen, Novartis, TEVA, Takeda, Roche, Abbvie and Pfizer. AP reports honoraria from Behring and Abbvie and has participated in Scientific Advisory Board meetings organized by Abbvie, Janssen-Cilag, Novartis, Pfizer and Takeda. RS has received research funding from Amgen, BMS, Celgene, Janssen-Cilag and Takeda and honoraria from the same companies (Advisory Board and presentations). MP has received honoraria from Amgen, Celgene, Janssen-Cilag and Takeda (Advisory Board and presentations).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}